Back to results
US 6,673,896 B1Granted
Derivatives of soluble T-4
AssigneeThe Trustees of Columbia University in the City of New York
InventorsPaul J. Maddon, Richard Axel
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeThe Trustees of Columbia University in the City of New York
InventorsPaul J. Maddon, Richard Axel
Estimating the term…
This invention provides a therapeutic agent capable of specifically forming a complex with human immunodeficiency virus envelope glycoprotein which comprises a polypeptide. In one embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +185 fused to the amino acid sequence from about +353 to about +371. In another embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +106 fused to the amino acid sequence from about +353 to about +371. In yet a further embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +185. This invention also provides a method for treating a subject infected with a human immunodeficiency virus. The method comprises administering to the subject an effective amount of a pharmaceutical composition comprising an effective amount of a therapeutic agent of the invention and a pharmaceutically acceptable carrier.
A hybrid protein consisting essentially of amino acids having the sequence shown in FIG. 6 from 1 to 106 fused to another polypeptide with the proviso that such another polypeptide does not have the sequence shown in FIG. 6 from 107 to 371 or from +353 to +371.
A hybrid protein consisting essentially of the below sequence:
Dependencies are inferred from the claim text.